Patented Medicine Prices Review Board
www.pmprb-cepmb.gc.ca
Home > Voluntary Compliance Undertakings
Voluntary Compliance Undertakings
A Voluntary Compliance Undertaking (VCU) is a written commitment by a patentee to comply with the Board´s Guidelines including adjusting its price to a non-excessive level and offsetting excess revenue. Patentees are given an opportunity to submit a VCU when Board Staff concludes, following an investigation, that the price of a patented drug product sold in Canada appears to have exceeded the Guidelines. A VCU can also be submitted following the issuance of a Notice of Hearing but must then be approved by the Hearing Panel.
The PMPRB publishes Voluntary Compliance Undertakings (VCUs) once they are approved by the Chairperson. As soon as a patentee has been informed that the terms of a VCU have been approved, the document becomes public and is reported in the NEWSletter and the Annual Report.
Summaries of VCUs by year
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
A
ABILIFY (February 2011)
ADENOSCAN (May 2010)
AIROMIR (May 2007)
- VCU by 3M Canada Company(PDF)
- Board Order(PDF)
- Press Release(PDF)
ANAPROX (August 1999)
ANDRIOL (September 2009)
ANDROGEL (June 2008)
AROMASIN (April 2003)
AVONEX PS (July 2012)
Top of page
B
BANZEL (November 2012)
BREVIBLOC (September 2009)
BUSULFEX (November 2004)
BUSULFEX (June 2010)
Top of page
C
CERETEC (July 2005)
CLARITIN (October 2009)
CONCERTA (April 2009)
- VCU by Janssen-Ortho Inc. (PDF)
- Board Order (PDF)
- Communiqué (PDF)
Top of page
D
DENAVIR (April 2008)
DICETEL (May 2010)
DIFFERIN PLEDGET (September 2002)
DIFLUCAN (May 2012)
DOSTINEX (October 2003)
DOVOBET (December 2007)
DOVOBET (January 2012)
DUKORAL (December 2005)
Top of page
E
EFFIENT (October 2011)
ELIGARD (March 2009)
- VCU by sanofi-aventis Canada Inc. (PDF)
ELOXATIN (June 2006)
EVRA (February 2005)
Top of page
F
FASLODEX (October 2010)
FASTURTEC (June 2004)
FSME-IMMUN (March 2010)
FORTEO (June 2007)
Top of page
H
HABITROL (October 1994)
HALAVEN (December 2012)
HEXTEND (July 2006)
HUMALOG (April 1998)
Top of page
L
LANTUS (March 2008)
LEVEMIR (May 2010)
LYRICA (November 2012)
Top of page
I
IFEX (December 2012)
Top of page
M
MAVIK (April 2013)
- VCU by Abbott Laboratories Limited (PDF)
MIOCHOL-E (September 2010)
N
NASONEX (October 2011)
NEULASTA (October 2009)
- VCU by Amgen Canada Inc.(PDF)
- Board Order (PDF)
- Communiqué (PDF)
NIASPAN (May 2011)
NUVARING™ (June 2006)
Top of page
O
ONE-ALPHA (May 2004)
ORGALUTRAN (October 2011)
ORTHO 7/7/7 (September 2005)
OCTREOSCAN (September 2007)
Top of page
P
PARIET (May 2012)
PAXIL CR (March 2010)
PAXIL CR (March 2005)
PLAVIX (June 2000)
PRECEDEX (March 2012)
PROCYTOX (December 2012)
PROLASTIN (July 2004)
Top of page
R
REMICADE ( March 31, 2003)
RISPERDAL (December 2005)
RISPERDAL CONSTA (June 2007)
- VCU by Janssen-Ortho Inc.(PDF)
- Board Order(PDF)
- Press Release(PDF)
Top of page
S
SINEMET CR (July 2011)
STARLIX (July 2005)
STARNOC (July 2004)
STRATTERA (February 2009)
- VCU by Eli Lilly Canada Inc. (PDF)
- Board Order (PDF)
- Communiqué (PDF)
SUPRANE (April 2011)
SUPRAX (March 2009)
Top of page
T
TACTUO (April 2013)
- VCU by Galderma Canada Inc. (PDF)
- Board Order (PDF)
TAMIFLU (March 2005)
TASIGNA (October 2010)
TECHNESCAN MAG3 (May 2011)
THALOMID (January 2012)
TRILEPTAL (May 2012)
TRINIPATCH (November 2009)
TRINIPATCH (May 2011)
Top of page
U
UROMITEXAN (December 2012)
Top of page
V
VANCOCIN (July 2010)
VANIQA (February 2008)
VEPESID (February 2009)
VOLUVEN (February 2010)
Top of page
X
XARELTO (January 2010)
Top of page
Z
ZANAFLEX (October 2001)
ZEMPLAR (September 2007)
- Board Order (PDF)
- VCU by Abbot Laboratories Canada (PDF)
- Communiqué (PDF)
Top of page